Related Experiment Video
Updated: Mar 8, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Autophagic dysregulation in doxorubicin cardiomyopathy
Jordan J Bartlett1, Purvi C Trivedi1, Thomas Pulinilkunnil1
1Department of Biochemistry and Molecular Biology, Faculty of Medicine, Dalhousie University, Dalhousie Medicine New Brunswick, 100 Tucker Park Road, Saint John E2L4L5, New Brunswick, Canada.
Abstract:
Doxorubicin (DOX)-induced cardiotoxicity has been a well-known phenomenon to clinicians and scientists for decades; however, molecular mechanisms underlying DOX cardiotoxicity are still being uncovered. Although the majority of prior research have implicated nuclear and mitochondrial events to be an important etiological aspects of DOX cardiomyopathy, recent discoveries in autophagy have highlighted the renewed interest in the role of lysosome in DOX cardiomyopathy. Indeed, dysregulation of lysosomal autophagy is observed in pre-clinical models of DOX cardiotoxicity. In this review, we provide a comprehensive overview on mechanisms describing regulation of the autophagy pathway by DOX and its influence on cardiotoxic outcomes. We have put specific emphasis on experimental models, dosing and treatment duration with DOX, and methods to monitor autophagy, all of which contribute to inconsistencies observed in the literature. We have clarified processes by which DOX dysregulates macroautophagy in the heart by primarily focusing on the contribution of LC3, p62, Beclin, mTOR and AMPK pathways. We have also highlighted the impact of DOX on mitochondrial reactive oxygen species (ROS) and its contribution to the process of mitophagy. We have presented mechanisms by which DOX compromises lysosomal acidification, integrity and chaperone-mediated autophagy through its effect on lysosome-associated and resident proteins such as LAMP, vATPase, Hsp90, Hsc70 and cathepsins. Furthermore, we have discussed novel pathways in DOX cardiotoxicity, the most prominent being DOX-induced loss of TFEB, a member of the MITF family of transcription factors, which governs lysosomal biogenesis and function. This review summarizes that in the myocardium, DOX dysregulates autophagy by impairing transcriptional factors regulating lysosomal function, thereby, precipitating proteotoxicity, mitochondrial dysfunction and cell death, thus rendering the heart susceptible to cardiomyopathic failure.
Insights
Doxorubicin (DOX) chemotherapy damages the heart by disrupting cellular waste removal (autophagy) and lysosome function. This review details how DOX impairs these processes, leading to heart failure.
Area of Science:
- Cardiology
- Molecular Biology
- Cell Biology
Background:
- Doxorubicin (DOX) is a widely used chemotherapy agent with known cardiotoxicity.
- While nuclear and mitochondrial mechanisms are established, the role of lysosomal autophagy in DOX cardiotoxicity is gaining attention.
- Dysregulation of lysosomal autophagy is observed in pre-clinical models of DOX cardiotoxicity.
Purpose of the Study:
- To provide a comprehensive overview of how DOX regulates autophagy and influences cardiotoxic outcomes.
- To emphasize experimental models, dosing, and monitoring methods that contribute to literature inconsistencies.
- To clarify the molecular mechanisms by which DOX dysregulates macroautophagy and mitophagy in the heart.
Main Methods:
- Review of existing literature on DOX cardiotoxicity and autophagy pathways.
- Focus on key proteins involved in macroautophagy (LC3, p62, Beclin, mTOR, AMPK).
- Analysis of DOX's impact on mitochondrial ROS and mitophagy.
- Examination of DOX effects on lysosomal function and associated proteins (LAMP, vATPase, Hsp90, Hsc70, cathepsins).
- Discussion of novel pathways, including TFEB's role.
Main Results:
- DOX dysregulates macroautophagy by affecting pathways involving LC3, p62, Beclin, mTOR, and AMPK.
- DOX exacerbates cardiotoxicity through increased mitochondrial ROS and impaired mitophagy.
- DOX compromises lysosomal acidification, integrity, and chaperone-mediated autophagy.
- DOX induces loss of TFEB, a transcription factor crucial for lysosomal biogenesis and function.
Conclusions:
- In the myocardium, DOX disrupts autophagy by impairing transcriptional factors that regulate lysosomal function.
- This leads to proteotoxicity, mitochondrial dysfunction, and cell death, ultimately causing cardiomyopathic failure.
- Understanding these mechanisms is crucial for developing strategies to mitigate DOX-induced cardiotoxicity.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Heart Failure Drugs: Inotropic Agents
Pathophysiology of Heart Failure
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Cardiomyopathy IV: Restrictive Cardiomyopathy

